Recombinant HCMV and RHCMV vectors and uses thereof
US11266732B2 · kind B2 · utility
0Cited by
23References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2018 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Apr 27, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.